Biotech Hit With Securities Class Action Over Sham Merger
A Massachusetts pharmaceutical and biotechnology company lost its investors tens of millions of dollars by lying about the company's prospects and the possibility of a merger, a shareholder said in a...To view the full article, register now.
Already a subscriber? Click here to view full article